Stacey Tkachuk1,2, Kyle Collins1,2, Mary H H Ensom3,4. 1. Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada. 2. Children's and Women's Health Centre of British Columbia, Vancouver, Canada. 3. Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada. ensom@mail.ubc.ca. 4. Children's and Women's Health Centre of British Columbia, Vancouver, Canada. ensom@mail.ubc.ca.
Abstract
BACKGROUND: In adults, the area under the concentration-time curve (AUC) divided by the minimum inhibitory concentration (MIC) is associated with better clinical and bacteriological response to vancomycin in patients with methicillin-resistant Staphylococcus aureus who achieve target AUC/MIC ≥ 400. This target is often extrapolated to pediatric patients despite the lack of similar evidence. The impracticalities of calculating the AUC in practice means vancomycin trough concentrations are used to predict the AUC/MIC. OBJECTIVE: This review aimed to determine the relationship between vancomycin trough concentrations and AUC/MIC in pediatric patients. METHODS: We searched the MEDLINE and Embase databases, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials using the medical subject heading (MeSH) terms vancomycin and AUC and pediatric* or paediatric*. Articles were included if they were published in English and reported a relationship between vancomycin trough concentrations and AUC/MIC. RESULTS: Of 122 articles retrieved, 11 met the inclusion criteria. One trial reported a relationship between vancomycin trough concentrations, AUC/MIC, and clinical outcomes but was likely underpowered. Five studies found troughs 6-10 mg/l were sufficient to attain an AUC/MIC > 400 in most general hospitalized pediatric patients. One study in patients undergoing cardiothoracic surgery found a trough of 18.4 mg/l achieved an AUC/MIC > 400. Two oncology studies reported troughs ≥ 15 mg/l likely attained an AUC/MIC ≥ 400. In critical care patients: one study found a trough of 9 mg/l did not attain the AUC/MIC target; another found 7 mg/l corresponded to an AUC/MIC of 400. CONCLUSIONS: Potential vancomycin targets varied based on the population studied but, for general hospitalized pediatric patients, troughs of 6-10 mg/l are likely sufficient to achieve AUC/MIC ≥ 400. For MIC ≥ 2 mg/l, higher troughs are likely necessary to achieve an AUC/MIC ≥ 400. More research is needed to determine the relationships between vancomycin trough concentrations, AUC/MIC, and clinical outcomes.
BACKGROUND: In adults, the area under the concentration-time curve (AUC) divided by the minimum inhibitory concentration (MIC) is associated with better clinical and bacteriological response to vancomycin in patients with methicillin-resistant Staphylococcus aureus who achieve target AUC/MIC ≥ 400. This target is often extrapolated to pediatric patients despite the lack of similar evidence. The impracticalities of calculating the AUC in practice means vancomycin trough concentrations are used to predict the AUC/MIC. OBJECTIVE: This review aimed to determine the relationship between vancomycin trough concentrations and AUC/MIC in pediatric patients. METHODS: We searched the MEDLINE and Embase databases, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials using the medical subject heading (MeSH) terms vancomycin and AUC and pediatric* or paediatric*. Articles were included if they were published in English and reported a relationship between vancomycin trough concentrations and AUC/MIC. RESULTS: Of 122 articles retrieved, 11 met the inclusion criteria. One trial reported a relationship between vancomycin trough concentrations, AUC/MIC, and clinical outcomes but was likely underpowered. Five studies found troughs 6-10 mg/l were sufficient to attain an AUC/MIC > 400 in most general hospitalized pediatric patients. One study in patients undergoing cardiothoracic surgery found a trough of 18.4 mg/l achieved an AUC/MIC > 400. Two oncology studies reported troughs ≥ 15 mg/l likely attained an AUC/MIC ≥ 400. In critical care patients: one study found a trough of 9 mg/l did not attain the AUC/MIC target; another found 7 mg/l corresponded to an AUC/MIC of 400. CONCLUSIONS: Potential vancomycin targets varied based on the population studied but, for general hospitalized pediatric patients, troughs of 6-10 mg/l are likely sufficient to achieve AUC/MIC ≥ 400. For MIC ≥ 2 mg/l, higher troughs are likely necessary to achieve an AUC/MIC ≥ 400. More research is needed to determine the relationships between vancomycin trough concentrations, AUC/MIC, and clinical outcomes.
Authors: David S Gomez; Edvaldo V Campos; Rodrigo P de Azevedo; João Manoel da Silva; Marcus C Ferreira; Cristina Sanches-Giraud; Carlindo Vieira Silva; Silvia R C J Santos Journal: Burns Date: 2012-08-04 Impact factor: 2.744
Authors: Pieter A J G De Cock; Sarah Desmet; Annick De Jaeger; Dominique Biarent; Evelyn Dhont; Ingrid Herck; Daphné Vens; Sofie Colman; Veronique Stove; Sabrina Commeyne; Johan Vande Walle; Peter De Paepe Journal: J Antimicrob Chemother Date: 2017-03-01 Impact factor: 5.790
Authors: Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli Journal: Pediatr Infect Dis J Date: 2013-04 Impact factor: 2.129
Authors: Shankar Lanke; Tian Yu; Joseph E Rower; Alfred H Balch; E Kent Korgenski; Catherine M Sherwin Journal: J Clin Pharmacol Date: 2016-07-15 Impact factor: 3.126
Authors: Julie C Fitzgerald; Nicole R Zane; Adam S Himebauch; Michael D Reedy; Kevin J Downes; Alexis A Topjian; Susan L Furth; Neal J Thomas; Marc H Scheetz; Athena F Zuppa Journal: Paediatr Drugs Date: 2019-04 Impact factor: 3.022